[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-331774-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-331774-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","fusion-genes-in-pancreatic-tumors","Fusion genes in pancreatic tumors","","Gene fusions and rearrangements are pivotal in tumor biology, especially in KRAS wild-type pancreatic tumors where such events are uncommon but clinically meaningful. Fusion profiling can guide precision oncology by revealing actionable targets involving BRAF, FGFR2, RET, NTRK, NRG1, and ALK, while also supporting diagnosis through characteristic fusions such as PRKACA/B in intraductal oncocytic papillary neoplasms. Despite their rarity, these genomic findings strengthen the case for high-quality molecular diagnostics. This review synthesizes existing evidence on fusion genes in pancreatic tumors and evaluates their biomarker and therapeutic potential.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/fusion-genes-in-pancreatic-tumors/331774/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/fusion-genes-in-pancreatic-tumors/331774.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are gene fusions important in pancreatic tumors?","Question",{"text":63,"@type":64},"Gene fusions and rearrangements play a crucial role in tumor biology and are particularly relevant in KRAS wild-type pancreatic tumors. Identifying them can support both clinical management and diagnostic interpretation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which fusion genes are described as actionable targets in KRAS wild-type pancreatic cancers?",{"text":68,"@type":64},"The abstract highlights fusions involving BRAF, FGFR2, RET, NTRK, NRG1, and ALK as actionable targets. These alterations enable precision oncology approaches for selected patients.",{"name":70,"@type":61,"acceptedAnswer":71},"How do fusion genes contribute to diagnosis in intraductal oncocytic papillary neoplasms (IOPNs)?",{"text":72,"@type":64},"The text states that fusions involving PRKACA/B serve as a diagnostic hallmark of IOPNs. This supports diagnostic purposes in addition to therapeutic decision-making.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},331774,1790075332,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Trends Cancer. Author manuscript; available in PMC 2026 August 30. |\n| --- | --- |\n\nPublished in final edited form as:  \nTrends Cancer. 2024 May ; 10(5): 430–443. doi:10.1016/j.trecan.2024.01.009 .  \nFusion genes in pancreatic tumors  \nAnastasios Gkountakos 1 , Aatur D. Singhi2 , C. Benedikt Westphalen3 , Aldo Scarpa 1,4,* , Claudio Luchini 1,4,*  \n1ARC-Net Research Center, University of Verona, Verona, Italy  \n2 Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA  \n3 Department of Medicine III and Comprehensive Cancer Centre (CCC), LMU University Hospital Munich and German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany  \n4 Department of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, Verona, Italy  \nAbstract  \nGene fusions and rearrangements play a crucial role in tumor biology. They are rare events typically detected in KRAS wild-type (WT) pancreatic tumors. Their identification can inform clinical management by enabling precision oncology, as fusions involving BRAF, FGFR2, RET, NTRK, NRG1, and ALK represent actionable targets in KRAS-WT cancers, and serve diagnostic purposes since fusions involving PRKACA/ B represent the diagnostic hallmark of intraductaloncocytic papillary neoplasms (IOPNs). Although they are rare, the therapeutic and diagnostic importance of these genomic events should not be underestimated, highlighting the need for quality-ensured molecular diagnostics in the management of cancer. Herein we review the existing literature on the role of fusion genes in pancreatic tumors and their clinical potential as effective biomarkers and therapeutic targets.  \nGene fusions in solid tumors  \nIn recent years, the advent of novel methodologies and platforms for DNA and RNA sequencing has led to vertical growth in our knowledge of the molecular characteristics of tumors [1] . Recent advances in these techniques have enabled the identification of structural rearrangements in cancer genomes [2,3]. Notably, some of these rearrangements are potential targets for precision oncology (see Glossary) [2–4] . Since the initial discovery  \nThis is an open access article under the CC BY license ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)).  \n*Correspondence: [aldo.scarpa@univr.it](aldo.scarpa@univr.it) (A. Scarpa) [and claudio.luchini@univr.it](and claudio.luchini@univr.it) (C. Luchini) .  \nDeclaration of interests  \nA.G. declares no competing interests. A.D.S. has the following conflict of interest: honorarium from Foundation Medicine, Inc.  \nC.B.W. has the following conflicts of interest: (i) honoraria from Amgen, Bayer, BMS, Chugai, Celgene, Falk, GSK, MSD, Merck, Janssen, Ipsen, Roche, Servier, SIRTeX, and Taiho; (ii) advisory boards for Bayer, BMS, Celgene, Janssen, MSD, Servier, Shire/ Baxalta, Rafael Pharmaceuticals, RedHill, and Roche; (iii) travel support from Bayer, Celgene, Janssen, RedHill, Roche, Servier, and Taiho; and (iv) research grants (institutional) from Roche. C.B.W. also serves as an officer for the European Society of Medical Oncology, Deutsche Krebshilfe, and Arbeitsgemeinschaft internistische Onkologie and is a member of the EU Commission Expert Group: Mission Board for Cancer. A.S. has the following conflicts of interest: consulting and speaker bureau from MSD, Incyte, Medica s.r.l., and NTP. C.L. has the following conflicts of interest: consulting and speaker bureau from MSD, Medica s.r.l., and NTP.  \nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript  \nGkountakos et al. Page 2  \nof the BCR-ABL fusion/Philadelphia chromosome in chronic myeloid leukemia [5], an increasing number of gene fusions have been identified in various types of solid tumors, starting with sarcomas [6], and these can serve as effective therapeutic ta","cbCaiqdIrNPzMnNB","https://ap.wps.com/l/cbCaiqdIrNPzMnNB","pdf",1058780,22,"English","# Gene fusions in solid tumors\n## Clinical relevance in KRAS wild-type pancreatic cancer\n## Diagnostic and therapeutic value of actionable fusions\n## Sequencing and assay strategies for fusion detection","[{\"question\":\"Why are gene fusions important in pancreatic tumors?\",\"answer\":\"Gene fusions and rearrangements play a crucial role in tumor biology and are particularly relevant in KRAS wild-type pancreatic tumors. Identifying them can support both clinical management and diagnostic interpretation.\"},{\"question\":\"Which fusion genes are described as actionable targets in KRAS wild-type pancreatic cancers?\",\"answer\":\"The abstract highlights fusions involving BRAF, FGFR2, RET, NTRK, NRG1, and ALK as actionable targets. These alterations enable precision oncology approaches for selected patients.\"},{\"question\":\"How do fusion genes contribute to diagnosis in intraductal oncocytic papillary neoplasms (IOPNs)?\",\"answer\":\"The text states that fusions involving PRKACA/B serve as a diagnostic hallmark of IOPNs. This supports diagnostic purposes in addition to therapeutic decision-making.\"}]","Fusion genes in pancreatic tumors | PDF",1789995050,55]